Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Consolidated Statements of Loss and Comprehensive Loss

v3.26.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Expenses      
Research and development $ 574,935 $ 183,830 $ 2,418,715
Consulting, wages and benefits 1,000,587 1,055,247 1,037,558
Directors' fees 215,568 168,143 179,406
Investor relations 595,838 1,360,170 919,490
Professional fees 349,328 616,859 514,263
General and administrative 241,032 320,949 375,505
Public company costs 120,335 141,404 170,184
Travel 21,121 31,916 170,187
Amortization of property and equipment 85,730 86,204 73,062
Amortization of intangible assets 26,385 31,070 66,632
Impairment of intangible assets 1,833    
Share-based payments 25,155 122,527 120,984
Loss before other items (3,257,847) (4,118,319) (6,045,986)
Fair value adjustment on derivative warrant liability 564,000 1,035,105 3,641,403
Foreign exchange loss (4,327) (73,009) (7,025)
Interest income 41,870 121,908 253,543
Transaction costs on derivative warrant liability   (279,031)  
Items that may be subsequently reclassified to profit or loss:      
Total loss and comprehensive loss for the year $ (2,656,304) $ (3,313,346) $ (2,158,065)
Basic and diluted loss per common share      
Basic loss per common share $ (0.56) $ (1.15) $ (1.09)
Diluted loss per common share $ (0.56) $ (1.15) $ (1.09)
Weighted average number of common shares outstanding      
Weighted average number of common shares outstanding, Basic 4,734,633 2,878,514 1,981,734
Weighted average number of common shares outstanding, Diluted 4,734,633 2,878,514 1,981,734